{"references": ["Vol. 3: N\u00ba 4; P\u00e1gs. 242-249. 2014. Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Translational Lung Cancer Research. DOI: http://dx.doi.org/10.3978/j.issn.2218-6751.2013.12.05", "Vol. 26: N\u00ba21; P\u00e1gs. 3552-3559. 2008. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology.", "Vol. 383: N\u00ba9928; P\u00e1gs. 1561-1571. 2014. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. DOI: https://doi.org/10.1016/S0140-6736(13)62159-5", "Vol. 40: N\u00ba6; P\u00e1gs. 586-597. 2022. Reck M, Remon J, Hellmann MD. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. Journal of Clinical Oncology.", "Vol. 30: N\u00ba2; P\u00e1gs. 215-220. 2020. Broderick SR. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer. Thoracic Surgery Clinic. DOI: https://doi.org/10.1016/j.thorsurg.2020.01.001", "FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer. News release. FDA. October 15, 2021. Accessed April 22, 2022."]}

La llegada de la inmunoterapia al arsenal terapéutico del cáncer de pulmón en la última década ha supuesto un cambio en el paradigma de la enfermedad. Con los buenos resultados obtenidos en pacientes metastásicos, la estrategia actual busca adelantar la inmunoterapia a estadios precoces como se explora en el ensayo clínico CheckMate-816 que comentamos.